Oncolytics announces updates data from GOBLET cohort 4

Oncolytics (ONCY) Biotech announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous cell anal carcinoma, SCAC, a setting with no U.S. Food and Drug Administration-approved treatment options. Previous analysis from this cohort has focused on second-line or later SCAC patients. As of the current data cut, four of 14 evaluable third-line patients receiving pelareorep and atezolizumab achieved objective responses, resulting in an objective response rate of approximately 29%. These responses included two complete responses and two partial responses. The median duration of response is approximately 17 months, indicating both depth and durability of clinical benefit in a heavily pretreated population. “As we continue to analyze the Goblet data, we are finding important trends that are helping to shape our clinical development strategy,” said Jared Kelly, Chief Executive Officer of Oncolytics. “When you isolate to anal cancer patients with two prior lines of treatment and see a strong signal like this, it points the arrow in a direct line to a registration study in an indication where there are no FDA-approved therapies. We already had good data here, but looking closer, it becomes clearer that we can make an immediate impact on patients’ lives who have no options.”